Merck & Co. to pay $1 billion upfront to buy Peloton Therapeutics gaining latestage renal cancer drug PT2977 httpswww.firstwordpharma.comnode1642305Â $MRK

Merck & Co. to pay $1 billion upfront to buy Peloton Therapeutics, gaining late-stage renal cancer drug PT2977 https://www.firstwordpharma.com/node/1642305  $MRK

08:04 EDT 21 May 2019 | FirstWord Pharma

Merck & Co. to pay $1 billion upfront to buy Peloton Therapeutics, gaining late-stage renal cancer drug PT2977 https://www.firstwordpharma.com/node/1642305  $MRK

More From BioPortfolio on "Merck & Co. to pay $1 billion upfront to buy Peloton Therapeutics, gaining late-stage renal cancer drug PT2977 https://www.firstwordpharma.com/node/1642305  $MRK"